Company Profile: Sistemic Ltd

By Reid Jim  

Regenerative Medicine, Vol. 8, Iss. 5, 2013-09 ,pp. : 549-552

Future Medicine

Access to resources Recommend Favorite

Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma?

By  

THE BREAST JOURNAL, Vol. 21, Iss. 5, 2015-09 ,pp. : 514-519

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk of recurrence of ductal carcinoma in situ by oncotype Dx technology: Some concerns

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1085-1085

John Wiley & Sons Inc

Access to resources Recommend Favorite

ONCOLOGISTS’ BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY

By  

International Journal of Technology Assessment in Health Care, Vol. 32, Iss. 5, 2016-12 ,pp. : 355-361

Cambridge University Press

Access to resources Recommend Favorite

Assignment¹ of the human peptide chain release factor 3 (GSPT2) to Xp11.23→p11.21 and of the distal marker DXS1039 by radiation hybrid mapping

By  

Cytogenetic and Genome Research, Vol. 86, Iss. 3-4, 1999-11 ,pp. : 250-251

Karger

Access to resources Recommend Favorite